In Vitro Longitudinal Relaxivity Profile Of Gd (Abe-Dtta), An Investigational Magnetic Resonance Imaging Contrast Agent
PLOS ONE(2016)
摘要
PurposeMRI contrast agents (CA) whose contrast enhancement remains relatively high even at the higher end of the magnetic field strength range would be desirable. The purpose of this work was to demonstrate such a desired magnetic field dependency of the longitudinal relaxivity for an experimental MRI CA, Gd(ABE-DTTA).Materials and MethodsThe relaxivity of 0.5mM and 1mM Gd(ABE-DTTA) was measured by Nuclear Magnetic Relaxation Dispersion (NMRD) in the range of 0.0002 to 1T. Two MRI and five NMR instruments were used to cover the range between 1.5 to 20T. Parallel measurement of a GdDTPA sample was performed throughout as reference. All measurements were carried out at 37 degrees C and pH 7.4.ResultsThe relaxivity values of 0.5mM and 1mM Gd(ABE-DTTA) measured at 1.5, 3, and 7T, within the presently clinically relevant magnetic field range, were 15.3, 11.8, 12.4 s(-1)mM(-1) and 18.1, 16.7, and 13.5 s(-1)mM(-1), respectively. The control 4 mM Gd-DTPA relaxivities at the same magnetic fields were 3.6, 3.3, and 3.0 s(-1)mM(-1), respectively.ConclusionsThe longitudinal relaxivity of Gd(ABE-DTTA) measured within the presently clinically relevant field range is three to five times higher than that of most commercially available agents. Thus, Gd(ABE-DTTA) could be a practical choice at any field strength currently used in clinical imaging including those at the higher end.
更多查看译文
关键词
vitro longitudinal relaxivity profile,gdabe-dtta,imaging
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要